298 related articles for article (PubMed ID: 34213775)
1. Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma.
Simmons C; Deyell RJ; MacNeill AJ; Vera-Badillo FE; Smrke A; Abdul Razak AR; Banerji S; McLeod D; Noujaim J
Int J Cancer; 2021 Nov; 149(9):1691-1704. PubMed ID: 34213775
[TBL] [Abstract][Full Text] [Related]
2. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding CP; Loong HH; Huang PH; Jones RL
Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318
[TBL] [Abstract][Full Text] [Related]
3. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
4. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
5. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
[TBL] [Abstract][Full Text] [Related]
7. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
[TBL] [Abstract][Full Text] [Related]
8. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients.
Perreault S; Chami R; Deyell RJ; El Demellawy D; Ellezam B; Jabado N; Morgenstern DA; Narendran A; Sorensen PHB; Wasserman JD; Yip S
Curr Oncol; 2021 Jan; 28(1):346-366. PubMed ID: 33435412
[TBL] [Abstract][Full Text] [Related]
9. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
10. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
11. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults.
Bebb DG; Banerji S; Blais N; Desmeules P; Gill S; Grin A; Feilotter H; Hansen AR; Hyrcza M; Krzyzanowska M; Melosky B; Noujaim J; Purgina B; Ruether D; Simmons CE; Soulieres D; Torlakovic EE; Tsao MS
Curr Oncol; 2021 Jan; 28(1):523-548. PubMed ID: 33467570
[TBL] [Abstract][Full Text] [Related]
12. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
14. NTRK Gene Fusion Detection in Atypical Spitz Tumors.
Cappellesso R; Nozzoli F; Zito Marino F; Simi S; Castiglione F; De Giorgi V; Cota C; Senetta R; Scognamiglio G; Anniciello AM; Cesinaro AM; Mandalà M; Gianatti A; Valente MG; Valeri B; Sementa AR; Ricci C; Corti B; Roviello G; Dei Tos AP; Franco R; Massi D
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830218
[TBL] [Abstract][Full Text] [Related]
15. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
16. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract][Full Text] [Related]
17. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
18. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
[TBL] [Abstract][Full Text] [Related]
19. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
20. S100 and Pan-Trk Staining to Report NTRK Fusion-Positive Uterine Sarcoma: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Chiang S
Int J Gynecol Pathol; 2021 Jan; 40(1):24-27. PubMed ID: 33290352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]